Archives of Medical Research
Volume 41, Issue 3 , Pages 215-220 , April 2010

Polymorphisms in NAT2 Gene and Atherosclerosis in an Algerian Population

  • Malika Khelil

      Affiliations

    • Département de Biologie Cellulaire et Moléculaire, Faculté des Sciences Biologiques, Université des Sciences et de la Technologie Houari Boumediène Alger, Algérie
    • Corresponding Author InformationAddress reprint requests to: Malika Khelil, Département de Biologie Cellulaire et Moléculaire, Faculté des Sciences Biologiques, Université des Sciences et de la Technologie Houari, Boumediene, BP: 32 El-Alia. 16111 Alger, Algérie; Phone: (213) 771239487; Fax: (213) 21247217
    • ,
  • Akila Zenati

      Affiliations

    • Laboratoire Central de Biologie–Centre Hospitalo-Universitaire (CHU), Bab el-Oued, Alger, Algeria
    • ,
  • Mohamed Makrelouf

      Affiliations

    • Laboratoire Central de Biologie–Centre Hospitalo-Universitaire (CHU), Bab el-Oued, Alger, Algeria
    • ,
  • Amel Otmane

      Affiliations

    • Laboratoire Central de Biologie–Centre Hospitalo-Universitaire (CHU), Bab el-Oued, Alger, Algeria
    • ,
  • Bouchentouf Tayebi

      Affiliations

    • Département de Biologie Cellulaire et Moléculaire, Faculté des Sciences Biologiques, Université des Sciences et de la Technologie Houari Boumediène Alger, Algérie

Received 27 August 2009 ,Accepted 19 March 2010.

References 

  1. Ross RE. Atherosclerosis: a defence mechanism gone awry. Am J Pathol. 1993;143:987–1002
  2. Ross RE. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London). 1993;562:801–809
  3. Chen T, Huang Z, Wang L, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res. 2009;83:131–139Epub 2009 Apr 17
  4. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–1792
  5. Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem. 2008;283:15527–15531
  6. Unal M, Tamer L, Doğruer ZN, et al. N-acetyltransferase 2 gene polymorphism and presbycusis. Laryngoscope. 2005;115:2238–2241
  7. Van Eyken E, Van Camp G, Fransen E, et al. Contribution of the N-acetyltransferase 2 polymorphism NAT2∗6A to age-related hearing impairment. J Med Genet. 2007;44:570–578
  8. Kinscherf R, Deigner HP. Apoptogenic signal transduction in arteriosclerosis-associated cells—opportunities for future therapy?. Vasc Dis Preven. 2008;5:116–128
  9. Ji Y, Gao S. Arylamine N-acetyltransferases: a new inhibitor of apoptosis in HepG2 cells. J Zhejiang Univ Sci. 2008;9:701–706
  10. Hein DW, Trinidad A, Yerokun T, et al. Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. Drug Metab Dispos. 1988;16:341–347
  11. Carreón T, Ruder AM, Schult PA, et al. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer. 2006;118:161–168
  12. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;25:1649–1658
  13. Sim E, Westwood I, Fullam E. Arylamine N-acetyltransferases. Exp Opin Drug Metab Toxicol. 2007;3:169–184
  14. Palmer LI, Martin RC, Hein DW. Chemopreventive drug treatments in subjects with genetic predisposition to cancer. Prescriber liability and healthcare disparities. Pharmacogenomics. 2004;5:319–329
  15. Windmill KF, Gaedigk A, Hall PM, et al. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000;54:19–29
  16. Husain A, Zhang X, Doll MA, et al. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos. 2007;35:721–727
  17. Izzotti A, Cartiglia C, Lewtas J, et al. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J. 2001;15:752–757
  18. Binková B, Šmerhovský Z, Strejc P, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res. 2002;501:115–128
  19. Lund AK, Lucero J, Lucas S, et al. Vehicular emissions induce vascular MMP-9 expression and activity associated with endothelin-1-mediated pathways. Arterioscler Thromb Vasc Biol. 2009;29:511–517
  20. Park SK, O'Neill MS, Vokonas PS, et al. Traffic-related particles are associated with elevated homocysteine: the VA normative aging study. Am J Respir Crit Care Med. 2008;178:283–289
  21. Arlt VM, Glatt H, Gamboa da Costa G, et al. Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone. Toxicol Sci. 2007;98:445–457
  22. Johnson JA, Humma LM. Pharmacogenetics of cardiovascular drugs. Briefing Func Genom Proteom. 2002;1:66–79
  23. Antila S, Pesonen U, Lehtonen L, et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci. 2004;23:213–222
  24. Niwa T, Shiraga T, Ohno Y, et al. Interindividual variability in 5-fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol Pharm Bull. 2005;28:1071–1074
  25. Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 2008;17:1143–1150
  26. Galvani S, Coatrieux C, Elbaz M, et al. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med. 2008;45:1457–1467
  27. Deitz AC, Zheng W, Leff MA, et al. N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomark Prev. 2000;9:905–910
  28. Whitley E, Ball J. Statistics review 4: Sample size calculations. Crit Care. 2002;6:335–341
  29. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440–9445
  30. Ilett KF, Gastleden WM, Vandongen YK, et al. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther. 1993;54:317–322
  31. Izzotti A, Piana A, Minniti G, et al. Survival of atherosclerotic patients as related to oxidative stress and gene polymorphisms. Mutat Res. 2007;621:119–128
  32. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation and GSTM null genotypes increase bladder cancer risk: results from the Spanish bladder cancer study and meta-analyses. Lancet. 2005;366:649–659
  33. Brockton N, Little J, Sharp L, et al. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol. 2000;15:846–861
  34. Huang CC, Chien WP, Wong RH, et al. NAT2 fast acetylator genotype and MGMT promoter methylation may contribute to gender difference in K-RAS mutation occurrence in Taiwanese colorectal cancer. Environ Mol Mutagen. 2009;50:127–133
  35. Deguchi M, Yoshida S, Kennedy S, et al. Lack of association between endometriosis and N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in a Japanese population. J Soc Gynecol Investig. 2005;12:208–213
  36. Bonisolli L, Pontirolli AE, De Pasqua A, et al. Association between chlorpropamide-alcohol flushing and fast acetylator phenotype in type I and type II diabetes. Acta Diabetol Lat. 1985;22:305–315
  37. Batra J, Ghosh B. N-acetyltransferases as markers for asthma and allergic/atopic disorders. Curr Drug Metab. 2008;9:546–553
  38. von Schmiedeberg S, Fritsche E, Rönnau AC, et al. Polymorphisms of the xenobiotic metabolizing enzymes CYP1A1and NAT2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol. 1999;455:147–152
  39. Rodriguez-Menocal L, Pham SM, Mateu D, et al. Aging increases p16 lnk4a expression in vascular smooth muscle cells. Biosci Rep. 2009;17:11–18
  40. Miller MC, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett. 2001;120:269–280
  41. Nakago S, Hadfield RM, Zondervan KT, et al. Association between endometriosis and N-acetyltransferase 2, polymorphisms in UK population. Mol Hum Reprod. 2001;7:1079–1083
  42. Luca F, Bubba G, Basile M, et al. Multiple advantageous amine acid variants in the NAT2 gene in human populations. Plos One. 2008;3:e3136
  43. Patin E, Hermant C, Kidd KK, et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat. 2006;27:720–730
  44. Badawi AF, Hirvonen A, Bell DA, et al. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in human urinary bladder. Cancer Res. 1995;55:5230–5237
  45. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res. 1997;376:61–70
  46. Sabbagh A, Langaney A, Darlu P, et al. Worldwide distribution of NAT2 diversity: implication for NAT2 evolutionary history. BMC Genet. 2008;27:9–21
  47. Makarova SI, Vavilin VA, Lyakhovich VV, et al. Allele NAT2∗5 determines resistance to bronchial asthma in children. Bull Exp Biol Med. 2000;129:575–577
  48. Hansen AM, Wallin H, Binderup ML, et al. Urinary 1-hydroxypyrene and mutagenicity in bus drivers and mail carriers exposed to urban air pollution in Denmark. Mutat Res. 2004;557:7–17
  49. Hein DW, Fretland A, Doll MA. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer. 2006;119:1208–1211
  50. Bendaly J, Metry KJ, Doll MA, et al. Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazole [4, 5-b] pyridine-induced mutagenicity and DNA adducts. Xenobiotica. 2009;19:1–8
  51. Olivera M, Martinez C, Molina JA, et al. Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand. 2006;113:322–326

PII: S0188-4409(10)00051-2

doi: 10.1016/j.arcmed.2010.03.008

Archives of Medical Research
Volume 41, Issue 3 , Pages 215-220 , April 2010

Article Tools